Video

Practical Considerations for Selection of PSMA-PET Tracers

Author(s):

Phillip Koo, MD,Michael S. Cookson, MD, MMHC

Experts discuss practical considerations on selection among available PSMA-PET tracer options for prostate cancer imaging, including regional availability, scheduling, and preparation requirements.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
      Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
      Dr Louise Kostos answers a question during a Zoom video interview
      An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
      Related Content
      Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
      May 2nd 2025

      Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

      Hannah Clarke
      The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      ARANOTE substudy highlights benefits of darolutamide in Black men
      April 28th 2025

      ARANOTE substudy highlights benefits of darolutamide in Black men

      Benjamin P. Saylor
      The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Stacy Loeb, MD, MSc, PhD | Credit: NYU Langone Health
      April 26th 2025

      TikTok, social media does more harm than good for prostate cancer education

      Patrick Campbell
      Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      April 25th 2025

      FDA clears AI-powered application for measuring prostate volume

      Benjamin P. Saylor
      Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.
      © 2025 MJH Life Sciences

      All rights reserved.